SCHEMBL5728797

SCHEMBL5728797

N#Cc1ccccc1CCBr

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 1/20 0.43
SMN1; SMN2 Q16637 5/20 0.42
ALDH1A1 P00352 3/20 0.42
MAPT P10636 1/20 0.42
TSHR P16473 3/20 0.41
CYP1A1 P04798 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP1B1 Q16678 1/20 0.40
TDP1 Q9NUW8 1/20 0.39
FFAR1 O14842 1/20 0.39
SLC6A2 P23975 1/20 0.36
SLC6A4 P31645 1/20 0.36
HPGD P15428 2/20 0.36
KDM4E B2RXH2 1/20 0.36
HSD17B10 Q99714 1/20 0.36
NPC1 O15118 2/20 0.35
RAB9A P51151 2/20 0.35
NPSR1 Q6W5P4 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30252315 1.00 CYP19A1 (0.43) CYP19A1SMN1; SMN2ALDH1A1MAPTTSHR
Methyl Alcohol SCHEMBL27754530 0.94 TSHR (0.42) CYP19A1SMN1; SMN2ALDH1A1MAPTTSHR
SCHEMBL7412881 0.88 CYP19A1 (0.41) CYP19A1SMN1; SMN2ALDH1A1MAPTTSHR
SCHEMBL2154210 0.86 SMN1; SMN2 (0.49) CYP19A1SMN1; SMN2ALDH1A1MAPTTSHR
SCHEMBL29633128 0.84 CYP19A1 (0.39) CYP19A1SMN1; SMN2ALDH1A1MAPTTSHR
SCHEMBL27532550 0.84 ESR2 (0.42) CYP19A1SMN1; SMN2ALDH1A1MAPTTSHR
SCHEMBL29513232 0.82 CYP19A1 (0.46) CYP19A1SMN1; SMN2ALDH1A1MAPTTSHR
SCHEMBL28248935 0.82 CYP19A1 (0.46) CYP19A1SMN1; SMN2ALDH1A1MAPTTSHR
SCHEMBL899 0.82 CYP19A1 (0.46) CYP19A1SMN1; SMN2ALDH1A1MAPTTSHR
SCHEMBL28248440 0.82 CYP19A1 (0.46) CYP19A1SMN1; SMN2ALDH1A1MAPTTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 115 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-104193726-A Synthesis method of alogliptin benzoate JIANGSU DEYUAN PHARMACEUTICAL CO LTD 2014-12-10 CN claimed
CN-104151291-A Preparation method for benzoic acid alogliptin polycrystalline type crystal JIANGSU DEYUAN PHARMACEUTICAL CO LTD 2014-11-19 CN claimed
CN-115427410-B Amide or sulfonamide derivatives and application thereof 苏州恩华生物医药科技有限公司 2024-02-23 CN disclosed
CN-115427410-A Amide or sulfonamide derivative and application thereof 苏州恩华生物医药科技有限公司 2022-12-02 CN disclosed
WO-2021213353-A1 AMIDE OR SULFONAMIDE DERIVATIVE AND USE THEREOF 苏州恩华生物医药科技有限公司 (CN) 2021-10-28 WO disclosed
CN-104080787-B Pyrazolo pyrrolidine compound 诺华股份有限公司 2016-09-14 CN disclosed
CN-104066732-B Novel antiviral Pyrrolopyridine derivatives and preparation method thereof KOREA CHEMICAL RESEARCH INSTITUTE (KR) 2016-04-13 CN disclosed
CN-102666545-B As the heterocycle Pyrazolopyrimidine analogs of JAK inhibitor CELLZOME LTD. (GB) 2016-04-06 CN disclosed
EP-2785717-B1 PYRAZOLOPYRROLIDINE COMPOUNDS NOVARTIS AG (CH) 2016-01-13 EP disclosed
CN-102459258-B Preparation and use of 1,2, 4-triazolo [1,5a ] pyridine derivatives CEPHALON, INC. (US) 2015-11-25 CN disclosed
CN-105051044-A Compounds and their use for modulating hemoglobin GLOBAL BLOOD THERAPEUTICS INC 2015-11-11 CN disclosed
CN-1112125-A Acyloxyhexanoic acid derivatives CIBA GEIGY AG (CH) 1995-11-22 CN disclosed
CN-1052672-A Benzofuran derivative GLAXO GROUP LTD (GB) 1991-07-03 CN disclosed
US-5015641-A Dipeptide for vision defects ANDREWS DAVID R (US) 1991-05-14 US disclosed
US-4885293-A CARBOXYALKYL DIPEPTIDES SCHERING CORPORATION (US) 1989-12-05 US disclosed
EP-0195817-B1 CARBOXYALKYLDIPEPTIDES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM SCHERING CORPORATION (US) 1989-10-18 EP disclosed
US-4826816-A Antihypertensive compounds SCHERING CORPORATION (US) 1989-05-02 US disclosed
CN-1030749-A The method for preparing Fungicidal compounds ICI PLC (GB) 1989-02-01 CN disclosed
US-4634698-A TOPICAL HYPOTENSIVES SCHERING CORPORATION (US) 1987-01-06 US disclosed
US-4556655-A TREATMENT OF CARDIOVASCULAR DISORDERS AND GLAUCOMA SCHERING CORPORATION (US) 1985-12-03 US disclosed